All In Biotech

Drug Trial Radar · NCT06315205

Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole LEBE at Different Strengths in Voluntary Healthy Post-Menopausal Women.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jul 26, 2023

Primary completion

Mar 11, 2026

Study completion Mar 11, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.

Conditions

  • Healthy

Interventions

  • Letrozole LEBE 75 mgDrug

    14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg

  • Letrozole LEBE 150 mgDrug

    14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg

  • Letrozole LEBE 225 mgDrug

    14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. λzTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  2. CmaxTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  3. ClastTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  4. tmaxTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  5. tlagTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  6. t1/2Time frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  7. AUC∞Time frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
  8. AUClastTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site number CZ-01

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.